FARN (FARN) News
Follow FARN (FARN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Faron Pharmaceuticals Ltd (FARON) Defers €1.4M Bond Amortization
Faron Pharmaceuticals and Heights Capital Management agreed to defer €1.4M of amortization due Oct 2, 2026 to the bonds’ maturities, and to defer Oct 2 interest to Dec 2, 2026 with no extra interest on the deferred inter
NEWS | Sep 30, 2026, 06:01 AM UTC
L
FARON FARN - Faron Pharmaceuticals LTD: Holding(S) In Company
FARON FARN - Faron Pharmaceuticals LTD: Holding(S) In Company
NEWS | Sep 17, 2026, 06:15 AM UTC
M
Faron issues 153,917 warrants and resets IPF warrant price to €0.4316
Faron Pharmaceuticals issued 153,917 additional warrants to IPF and reset the subscription price of all IPF-held warrants to €0.4316. IPF holds 3,795,384 warrants, each exercisable 1:1 for seven years.
EQUITY | Sep 17, 2026, 06:07 AM UTC
L
FARON FARN - Faron Announces R&D Day
FARON FARN - Faron Announces R&D Day
EQUITY | Sep 10, 2026, 06:15 AM UTC
L
FARON FARN - Faron Pharmaceuticals Ltd: Holding(s) in Company
FARON FARN - Faron Pharmaceuticals Ltd: Holding(s) in Company
EQUITY | Sep 07, 2026, 03:45 PM UTC
L
Faron Pharmaceuticals: holdings in company disclosed
Faron Pharmaceuticals Ltd has released information on holdings in the company.
EQUITY | Sep 04, 2026, 10:20 AM UTC
L
Faron Pharmaceuticals files notification of major holdings in company
Faron Pharmaceuticals Ltd issued a standard notification of major holdings in the company, as a company announcement dated September 04, 2026.
EQUITY | Sep 04, 2026, 10:00 AM UTC
L
Faron Pharmaceuticals (H1 Review): Setting up for an eventful period of clinical development
Faron Pharmaceuticals (H1 Review): Setting up for an eventful period of clinical development
EQUITY | Aug 28, 2026, 08:35 AM UTC
L
Faron says first patient enrolled in BEXAR trial
Faron announced the first patient has been enrolled in its BEXAR investigator-initiated trial.
EQUITY | Aug 27, 2026, 06:01 AM UTC
L
FARN: Bexmarilimab leads HR MDS innovation, backed by strong funding and advancing pivotal trials
FARN: Bexmarilimab leads HR MDS innovation, backed by strong funding and advancing pivotal trials
EQUITY | Aug 26, 2026, 02:01 PM UTC
M
FARN: Bexmarilimab reports 45% CR in HR-MDS
FARN says its Bexmarilimab delivered 45% CR in HR-MDS and that EUR 40M raised secures funding through 2027 milestones.
EQUITY | Aug 26, 2026, 01:21 PM UTC
M
FARN: Bexmarilimab reports 45% remission in high-risk MDS
FARN said its bexmarilimab achieved 45% remission in high-risk MDS, and that funding has been secured for pivotal trials.
EQUITY | Aug 26, 2026, 12:57 PM UTC
L
FARON FARN - Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results
FARON FARN - Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results
EQUITY | Aug 19, 2026, 06:25 AM UTC